Fulcrum Therapeutics is a biotechnology company that focuses on identifying and treating rare genetic diseases at their root cause.
Fulcrum Therapeutics has raised $175.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in December 2025.
Fulcrum Therapeutics's investors include Perceptive Advisors, Foresite Capital, Sanofi, Fidelity, Samsara BioCapital.
Fulcrum Therapeutics is headquartered in Cambridge, United States.
Fulcrum Therapeutics is a biotechnology company that focuses on identifying and treating rare genetic diseases at their root cause.
Fulcrum Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Fulcrum Therapeutics — Funding & Investors." VCBacked, December 10, 2025, https://www.vcbacked.co/company/fulcrum-therapeutics. Accessed September 30, 2026.
VCBacked. (2025). Fulcrum Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/fulcrum-therapeutics
{{cite web |title=Fulcrum Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/fulcrum-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated